Company intelligence / Profile preview

Iricor Therapeutics

Los Angeles, California, United States

Ownership: Private
Development stage: Other

Overview

Iricor Therapeutics is a pre-clinical stage biotechnology company focused on developing first-in-class topical therapies for ophthalmic conditions. The company's lead research involves leveraging thyroid hormone signaling to stimulate corneal nerve regeneration and accelerate wound healing. By targeting the underlying mechanisms of corneal injury and dry eye disease, Iricor aims to provide more effective treatments for patients suffering from ocular surface disorders and neurotrophic keratitis. The company's approach represents a novel application of hormonal regulation to restore ocular health and function.

Therapeutic areas: OphthalmologyDermatology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Iricor Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Iricor Therapeutics.

Explore the full profile